New FDA-Approved Dosing Schedule for Donanemab May Reduce ARIA-E Rates
Findings from the TRAILBLAZER-ALZ 6 study revealed a 41 percent reduction of the ARIA-E side effect at 24 weeks with the new dosing schedule for the anti-amyloid treatment donanemab-azbt.
The Food and Drug Administration (FDA) has approved dosing changes for the anti-amyloid therapy donanemab-azbt, which is utilized in the treatment of patients with early symptomatic Alzheimer’s disease.
Emphasizing a modified titrated dosing schedule, the new dosing for donanemab-azbt (Kisunla, Lilly) reportedly shifts a single vial from initial dosing to the third dose.
In the recent TRAILBLAZER-ALZ 6 study, researchers found that the modified dosing for donanemab-azbt facilitated a 41 percent reduction of amyloid-related imaging abnormalities with edema/effusion (ARIA-E) at 24 weeks and a 35 percent reduction at 52 weeks in comparison to the original dosing for the anti-amyloid therapy.
"This updated dosing strategy is a meaningful advancement for patients and their care teams," said Elly Lee, MD, chief medical officer and principal investigator at the Irvine Center for Clinical Research in Irvine, Calif. "By significantly reducing the risk of ARIA-E, we can offer patients and care teams greater confidence in the safety of Kisunla while preserving its ability to reduce amyloid."
Newsletter
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Recent Videos
Related Content
Large Medicare Study Shows Black Men Less Likely to Receive PET and MRI for Prostate Cancer Imaging
August 1st 2025Article
An analysis of over 749,000 Medicare beneficiaries diagnosed with prostate cancer over a five-year period found that Black men were 13 percent less likely to receive PET imaging and 16 percent less likely to receive MRI in comparison to White men.
The Reading Room Podcast: A Closer Look at Remote MRI Safety, Part 3
August 1st 2025Podcast
In the third of a three-part podcast episode, Emanuel Kanal, M.D. and Tobias Gilk, MRSO, MRSE, discuss strategies for maintaining the integrity of time-out procedures and communication with remote MRI scanning.
The Reading Room Podcast: A Closer Look at Remote MRI Safety, Part 2
August 1st 2025Podcast
In the second of a multi-part podcast episode, Emanuel Kanal, M.D. and Tobias Gilk, MRSO, MRSE, share their perspectives on remote MRI safety protocols for ensuring screening accuracy and adherence to conditional implant guidelines as well as a rapid and effective response to adverse events.
Study Reveals Significant Prevalence of Abnormal PET/MRI and Dual-Energy CT Findings with Long Covid
August 1st 2025Article
In a prospective study involving nearly 100 patients with Long Covid, 57 percent of patients had PET/MRI abnormalities and 90 percent of the cohort had abnormalities on dual-energy CT scans.
